#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal cancer recurrent Phaeochromocytoma Pyruvate dehydrogenase complex deficiency Prodromal Alzheimer's disease Desmoplastic small round cell tumour Juvenile idiopathic arthritis Human papilloma virus immunisation B-cell small lymphocytic lymphoma recurrent Obliterative bronchiolitis Acute leukaemia Liposarcoma recurrent Duchenne muscular dystrophy Follicular lymphoma stage III Hepatoblastoma Cutaneous T-cell lymphoma recurrent More trials…

    Learn about Rare Diseases

    Medulloblastoma Mucous membrane pemphigoid – Diagnostics Pleural mesothelioma malignant – Basic Information Rhabdomyosarcoma recurrent – Basic Information Undifferentiated sarcoma – Life with Disease Congenital hypotransferrinaemia – Trials in Disease Glomerulonephritis membranous – Trials in Disease Langerhans’ cell histiocytosis – Diagnostics Haemophilia A with anti factor VIII – Treatment Small intestine leiomyosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Acetate Trihydrate Pbf-999 Eo2317 H2-Receptor Antagonist Holcus Lanatus Pollen Extract Eculizumab Garadacimab Hydrocortisone Hemisuccinate Efavirenz Dipyridamole GRAPHITE Lovastatin Ifosfamide Quavonlimab Vgl101 Olopatadine Ralinepag Betamethasone Acetate Terlipressin Acetate Linerixibat More therapies…

    Learn about Your Condition

    Agitation postoperative Dementia with Lewy bodies Netherton's syndrome Colon cancer stage IV Respiratory tract infection Aneurysm ruptured Peritoneal cancer index Hairy cell leukaemia recurrent Small intestine adenocarcinoma Nephrogenic anaemia Multiple sclerosis Myotonia ROHHAD syndrome Desmoid tumour Pancreatitis chronic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Staphylococcal bacteraemia
    Investigated Drugs:
    • Sodium Chloride
    Germany

  • Adalimumab, Doxycycline, and Resorcinol for Adults with Early Hidradenitis Suppurativa at High Risk of Progression to Severe Disease

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Doxycycline
    • Adalimumab
    Denmark

  • Privosegtor Added to Standard IV Methylprednisolone in Patients with Optic Neuritis: Randomized Placebo‑Controlled Trial

    Not yet recruiting

    3 1
    France Germany Italy Poland Spain

  • A Randomized Double‑Blind Study of Pharmacokinetic Similarity of AVT32‑DRL_PB and Pembrolizumab in Patients with Resected Stage IIB‑C‑III Melanoma

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Romania Spain

  • Long‑term safety of IMA203 and IMA203CD8 autologous T‑cell therapy in patients with previously treated advanced or metastatic solid tumors

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Ima203Cd8
    • AUTOLOGOUS T-CELLS TRANSDUCED WITH THE LENTIVIRAL LV-R11KEA ENCODING T-CELL RECEPTOR TARGETING PATIENT-SPECIFIC TUMOR-ASSOCIATED ANTIGENS
    Germany

  • Safety and tolerability of OV329 as add‑on therapy in adults with drug‑resistant focal epilepsy

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Partial seizures
    The Netherlands
Previous Page
1 … 657 658 659 660 661 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!